Advertisement
Screener

IGC PHARMA, INC. (IGC) Repayments of Long-Term Debt

2.8 / 5 stars · 68/120 Roast Me

IGC PHARMA, INC. Repayments of Long-Term Debt

IGC PHARMA, INC. (IGC) reported Repayments of Long-Term Debt of $3.00 thousand for the 9-month period ending 2025-12-31, per its 10-KT filed 2026-03-18.

Financial Statements › Cash Flow › Financing Activities

us-gaap:RepaymentsOfLongTermDebt · last filed 2026-03-18

  • IGC PHARMA, INC. repayments of long-term debt for the quarter ending 2025-12-31 was $1.00K, a 0.00% change year-over-year.
  • IGC PHARMA, INC. repayments of long-term debt for the quarter ending 2025-03-31 was $0.00.
  • IGC PHARMA, INC. repayments of long-term debt for the quarter ending 2024-12-31 was $1.00K.
  • IGC PHARMA, INC. repayments of long-term debt for the quarter ending 2019-12-31 was $0.00, a 100.00% decline year-over-year.
  • IGC PHARMA, INC. repayments of long-term debt for fiscal 2025 was $3.00K.
  • IGC PHARMA, INC. repayments of long-term debt for fiscal 2012 was $0.00.
  • IGC PHARMA, INC. repayments of long-term debt for fiscal 2011 was $0.00.
Period endRepayments of Long-term Debt 3 monthRepayments of Long-term Debt 3 month as first filedRepayments of Long-term Debt 6 monthRepayments of Long-term Debt 9 monthRepayments of Long-term Debt 12 month
2025-12-31$1.00K
derived: 10-KT 9 month − 10-Q 6 month · filed 2026-03-18
$3.00K
10-KT · filed 2026-03-18
2025-09-30$2.00K
10-Q · filed 2025-11-14
2025-03-31$0.00
derived: 10-KT 12 month − 10-KT 9 month · filed 2026-03-18
$1.00K
derived: sum of 2 quarters · filed 2026-03-18
$3.00K
10-KT · filed 2026-03-18
2024-12-31$1.00K
derived: 10-KT 9 month − 10-Q 6 month · filed 2026-03-18
$3.00K
10-KT · filed 2026-03-18
2024-09-30$2.00K
10-Q · filed 2025-11-14
2019-12-31$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-02-10
$0.00
derived: sum of 2 quarters · filed 2020-02-10
$0.00
10-Q · filed 2020-02-10
2019-09-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-11-06
$0.00
10-Q · filed 2019-11-06
2019-06-30$0.00
10-Q · filed 2019-08-09
2018-12-31$1.68M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-02-10
$1.68M
derived: sum of 2 quarters · filed 2020-02-10
$1.88M
10-Q · filed 2020-02-10
2018-09-30$1.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-11-06
$202.00K
10-Q · filed 2019-11-06
2018-06-30$201.00K
10-Q · filed 2019-08-09
$201.13K
10-Q · filed 2018-08-03
2017-12-31$13.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-02-12
-$172.84K
derived: sum of 2 quarters · filed 2019-02-12
$107.00K
10-Q · filed 2019-02-12
2017-09-30-$185.84K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-10-16
$94.00K
10-Q · filed 2018-10-16
2017-06-30$279.84K
10-Q · filed 2018-08-03
2012-03-31$0.00
10-K · filed 2012-07-16
2011-03-31-$200.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2012-07-16
$0.00
10-K · filed 2012-07-16
2010-12-31$200.00K
10-Q · filed 2012-02-16

Similar stocks

Stock NameCountryMarket CapPE Ratio
Hepion Pharmaceuticals, Inc. (HEPA)United States$0.029B-0.62
Transcode Therapeutics, Inc. (RNAZ)United States$0.029B-0.12
KYNTRA BIO, INC. (KYNB)United States$0.028B0.17
BeyondSpring Inc. (BYSI)United States$0.031B-10.95
NANOVIRICIDES, INC. (NNVC)United States$0.031B
CHINA PHARMA HOLDINGS, INC. (CPHI)$0.032B
Propanc Biopharma, Inc. (PPCB)$0.032B-0.13
AYTU BIOPHARMA, INC (AYTU)United States$0.025B-1.62
Context Therapeutics Inc. (CNTX)United States$0.034B-1.10
NextCure, Inc. (NXTC)United States$0.024B-0.15